Structure Therapeutics (NASDAQ:GPCR) Now Covered by Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report report published on Wednesday, MarketBeat reports. The firm issued a buy rating and a $50.00 price target on the stock.

A number of other analysts have also weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities restated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Morgan Stanley started coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Stock Down 0.5 %

Structure Therapeutics stock opened at $27.04 on Wednesday. The firm has a fifty day simple moving average of $32.63 and a two-hundred day simple moving average of $36.70. Structure Therapeutics has a twelve month low of $25.90 and a twelve month high of $62.74. The company has a market capitalization of $1.55 billion, a PE ratio of -36.54 and a beta of -2.78.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after purchasing an additional 1,122 shares during the period. Sandia Investment Management LP bought a new stake in shares of Structure Therapeutics in the 2nd quarter worth approximately $39,000. Assetmark Inc. grew its stake in shares of Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares during the last quarter. Quarry LP bought a new position in Structure Therapeutics during the 2nd quarter valued at approximately $79,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after buying an additional 1,420 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.